Your browser doesn't support javascript.
loading
Intratumor heterogeneity index of breast carcinomas based on DNA methylation profiles.
Campoy, Emanuel M; Branham, María T; Mayorga, Luis S; Roqué, María.
Afiliación
  • Campoy EM; IHEM-CONICET, Av del libertador, 80, Mendoza, Argentina. ecampoy@mendoza-conicet.gob.ar.
  • Branham MT; Facultad de Ciencias Médicas, Av del Libertador 80, Universidad Nacional de Cuyo, Mendoza, Argentina. ecampoy@mendoza-conicet.gob.ar.
  • Mayorga LS; IHEM-CONICET, Av del libertador, 80, Mendoza, Argentina.
  • Roqué M; IHEM-CONICET, Av del libertador, 80, Mendoza, Argentina.
BMC Cancer ; 19(1): 328, 2019 Apr 05.
Article en En | MEDLINE | ID: mdl-30953488
ABSTRACT

BACKGROUND:

Cancer cells evolve and constitute heterogeneous populations that fluctuate in space and time and are subjected to selection generating intratumor heterogeneity. This phenomenon is determined by the acquisition of genetic/epigenetic alterations and their selection over time which has clinical implications on drug resistance.

METHODS:

DNA extracted from different tumor cell populations (breast carcinomas, cancer cell lines and cellular clones) were analyzed by MS-MLPA. Methylation profiles were used to generate a heterogeneity index to quantify the magnitude of epigenetic heterogeneity in these populations. Cellular clones were obtained from single cells derived of MDA-MB 231 cancer cell lines applying serial limiting dilution method and morphology was analyzed by optical microscopy and flow cytometry. Clones characteristics were examined through cellular proliferation, migration capacity and apoptosis. Heterogeneity index was also calculated from beta values derived from methylation profiles of TCGA tumors.

RESULTS:

The study of methylation profiles of 23 fresh breast carcinomas revealed heterogeneous allele populations in these tumor pieces. With the purpose to measure the magnitude of epigenetic heterogeneity, we developed an heterogeneity index based on methylation information and observed that all tumors present their own heterogeneity level. Applying the index calculation in pure cancer cell populations such as cancer cell lines (MDA-MB 231, MCF-7, T47D, HeLa and K-562), we also observed epigenetic heterogeneity. In addition, we detected that clones obtained from the MDA-MB 231 cancer cell line generated their own new heterogeneity over time. Using TCGA tumors, we determined that the heterogeneity index correlated with prognostic and predictive factors like tumor size (p = 0.0088), number of affected axillary nodes (p = 0.007), estrogen receptor expression (p < 0.0001) and HER2 positivity (p = 0.0007). When we analyzed molecular subtypes we found that they presented different heterogeneity levels. Interestingly, we also observed that all mentioned tumor cell populations shared a similar Heterogeneity index (HI) mean.

CONCLUSIONS:

Our results show that each tumor presents a unique epigenetic heterogeneity level, which is associated with prognostic and predictive factors. We also observe that breast tumor subtypes differ in terms of epigenetic heterogeneity, which could serve as a new contribution to understand the different prognosis of these groups.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Carcinoma Ductal de Mama / Metilación de ADN / Epigénesis Genética Tipo de estudio: Prognostic_studies Límite: Adult / Female / Humans Idioma: En Revista: BMC Cancer Asunto de la revista: NEOPLASIAS Año: 2019 Tipo del documento: Article País de afiliación: Argentina

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Carcinoma Ductal de Mama / Metilación de ADN / Epigénesis Genética Tipo de estudio: Prognostic_studies Límite: Adult / Female / Humans Idioma: En Revista: BMC Cancer Asunto de la revista: NEOPLASIAS Año: 2019 Tipo del documento: Article País de afiliación: Argentina